Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oxlumo
Pharma
Novo Nordisk eyes showdown with Alnylam with new FDA nod
Novo Nordisk is gearing up to launch its new rare disease offering in early 2024.
Eric Sagonowsky
Oct 2, 2023 1:36pm
Alnylam founding CEO Maraganore steps down
Oct 28, 2021 11:05am
Alnylam maps aggressive plan to catapult into biotech's top 5
Jan 11, 2021 12:39pm
Alnylam nets FDA nod for Oxlumo, its 3rd rare disease drug
Nov 24, 2020 8:00am
Alnylam scores European approval for rare disease med Oxlumo
Nov 19, 2020 8:57am
